Product Description
Livzon Pharma is developing LZ001 tablets, a small molecule ROS1/NTRK/ALK multi-kinase Inhibitor.
Mechanisms of Action: ROS1 Inhibitor,ALK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Pharmaceutical Group Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20221852 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |